2025
Human vs. AI: A comparative effectiveness study of large language models for automated biomarker extraction.
Hung T, Shin E, Yu Y, Riaz N, Lee N, Kang J. Human vs. AI: A comparative effectiveness study of large language models for automated biomarker extraction. Journal Of Clinical Oncology 2025, 43: e13605-e13605. DOI: 10.1200/jco.2025.43.16_suppl.e13605.Peer-Reviewed Original ResearchHPV statusLanguage modelMemorial Sloan Kettering Cancer CenterHead & neck cancerNatural language processing capabilitiesCancer registry reportsProcessing timeLanguage processing capabilitiesIndividual patient careComparative effectiveness studiesManual extractionBiomarker dataP16 statusP16+Neck cancerPatient careEnhance scalabilityF1 scoreOncology populationHPVReal-time integrationScalable solutionRegistry reportsCancer CenterP16
2024
Protocol for a randomized controlled trial of brief behavioral activation among older adult cancer survivors
Saracino R, Park E, Demirjian C, Jutagir D, McConnell K, Schofield E, Raue P, Lejuez C, Nelson C. Protocol for a randomized controlled trial of brief behavioral activation among older adult cancer survivors. Journal Of Geriatric Oncology 2024, 15: 101719. PMID: 38342735, PMCID: PMC11153038, DOI: 10.1016/j.jgo.2024.101719.Peer-Reviewed Original ResearchOlder adult cancer survivorsAdult cancer survivorsRandomized Controlled TrialsCancer survivorsWeekly sessionsDepressive symptomsTargeted interventionsEvaluate implementation outcomesElevated depressive symptomsMemorial Sloan Kettering Cancer CenterHistory of cancerSupportive psychotherapyClinically significant depressionSessions of BAIncreased activity levelsEvidence-based treatmentsCancer survivorshipOutpatient oncologySurvivorship clinicPost-cancerHealthcare outcomesPreliminary effectivenessImplementation outcomesMild cognitive impairmentPost-intervention
2023
A Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Bewersdorf J, Derkach A, Masarova L, Pemmaraju N, Stein E, Mauro M, Rampal R, Bose P. A Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. Blood 2023, 142: 6440. DOI: 10.1182/blood-2023-174322.Peer-Reviewed Original ResearchDuration of responseMaximum tolerated doseDose of ruxolitinibCDK4/6 inhibitorsStable doseTolerated doseHormone receptor-positive metastatic breast cancerRisk of progression to acute myeloid leukemiaSymptom scoresPhase I dose-escalation trialProgression to acute myeloid leukemiaTreatment of hormone receptor-positive metastatic breast cancerAbsolute neutrophil count <Cancer CenterCombination of CDK4/6 inhibitorsUS FDAMemorial Sloan Kettering Cancer CenterGrade 1 diarrheaMedian overall survivalPre-study doseDose-limiting toxicityMD Anderson Cancer CenterBone marrow fibrosisNeutrophil count <Platelet count <
2021
Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality
Stahl M, Narendra V, Jee J, Derkach A, Maloy M, Geyer M, Mato A, Roeker L, Tallman M, Shah G, Daniyan A, Goldberg A. Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality. Leukemia & Lymphoma 2021, 62: 1940-1948. PMID: 34180767, PMCID: PMC10080398, DOI: 10.1080/10428194.2021.1885664.Peer-Reviewed Original ResearchConceptsAdult acute myeloid leukemia patientsAcute myeloid leukemia patientsMemorial Sloan Kettering Cancer CenterCourse of COVID-19 infectionAssociated with increased odds of deathDiagnosis of AMLClinical course of COVID-19 infectionMyeloid leukemia patientsFlow nasal cannulaAssociated with increased oddsOdds of deathClinical courseHematologic malignanciesChronic leukemiaNasal cannulaLeukemia patientsCOVID-19 infectionMechanical ventilationPoor outcomeCancer CenterActive treatmentLeukemia subtypesRelated mortalityPatientsRisk factorsDigital Pathology Operations at an NYC Tertiary Cancer Center During the First 4 Months of COVID-19 Pandemic Response
Ardon O, Reuter V, Hameed M, Corsale L, Manzo A, Sirintrapun S, Ntiamoah P, Stamelos E, Schueffler P, England C, Klimstra D, Hanna M. Digital Pathology Operations at an NYC Tertiary Cancer Center During the First 4 Months of COVID-19 Pandemic Response. Academic Pathology 2021, 8: 23742895211010276. PMID: 35155745, PMCID: PMC8819741, DOI: 10.1177/23742895211010276.Peer-Reviewed Original ResearchPublic health emergencyHealth care delivery modelsCare delivery modelsCancer CenterPatients seeking careHealth emergencyLack of public transportationPresence of staffCOVID-19 pandemic regulationsHealth careCOVID-19 pandemic responseTertiary cancer centerDelivery modelsFamily supportOn-site presenceDevelopment of standard operating proceduresNew York CityWorkspace flexibilityClinical operationsPathology staffStaffPathology servicesPandemic responseCareMemorial Sloan Kettering Cancer Center
2020
Venetoclax Therapy for Relapsed and Treatment Refractory AML: Clinical Outcomes and Molecular Predictors
Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, King A, Daniyan A, Famulare C, Cuello B, Abdel-Wahab O, Levine R, Viny A, Stein E, Roshal M, Tallman M, Goldberg A. Venetoclax Therapy for Relapsed and Treatment Refractory AML: Clinical Outcomes and Molecular Predictors. Blood 2020, 136: 47-48. DOI: 10.1182/blood-2020-137815.Peer-Reviewed Original ResearchCurrent equity holderEntity's Board of DirectorsRR-AMLRR-AML patientsMeasurable residual diseaseOverall survivalCombination therapyVenetoclax therapyAdverse cytogeneticsComplete responseResponse rateMedian OSRefractory AMLResidual diseaseEuropean LeukemiaNetMolecular predictorsClinical outcomesADC therapeuticsAssociated with prolonged OSCycle 1 day 1Venetoclax-based combination therapiesAllogeneic stem cell transplantationLevel of residual diseaseAssociated with poor OSMemorial Sloan Kettering Cancer CenterValidation of a digital pathology system including remote review during the COVID-19 pandemic
Hanna M, Reuter V, Ardon O, Kim D, Sirintrapun S, Schüffler P, Busam K, Sauter J, Brogi E, Tan L, Xu B, Bale T, Agaram N, Tang L, Ellenson L, Philip J, Corsale L, Stamelos E, Friedlander M, Ntiamoah P, Labasin M, England C, Klimstra D, Hameed M. Validation of a digital pathology system including remote review during the COVID-19 pandemic. Modern Pathology 2020, 33: 2115-2127. PMID: 32572154, PMCID: PMC7306935, DOI: 10.1038/s41379-020-0601-5.Peer-Reviewed Original ResearchConceptsDigital pathology systemPathological specimensMemorial Sloan Kettering Cancer CenterReporting of pathology specimensClinical Laboratory Improvement Amendments regulationsRemote reviewVirtual private networkImage file sizeConsumer-grade computersPerineural invasionPathological stageWhole slide imagesMargin statusPrivate networkProspective studyPublic health emergencyFile sizeAccess performanceImage viewerAncillary testsDiagnostic concordancePathology systemMicroscopic diagnosisCancer CenterCase-based
2019
Whole slide imaging equivalency and efficiency study: experience at a large academic center
Hanna M, Reuter V, Hameed M, Tan L, Chiang S, Sigel C, Hollmann T, Giri D, Samboy J, Moradel C, Rosado A, Otilano J, England C, Corsale L, Stamelos E, Yagi Y, Schüffler P, Fuchs T, Klimstra D, Sirintrapun S. Whole slide imaging equivalency and efficiency study: experience at a large academic center. Modern Pathology 2019, 32: 916-928. PMID: 30778169, DOI: 10.1038/s41379-019-0205-0.Peer-Reviewed Original ResearchConceptsWhole slide imagesSlide imagesInformation systemsImage file sizeClinical workflowDigital pathologyLaboratory information systemSystem test environmentFile sizeImage viewerMemorial Sloan Kettering Cancer CenterPrimary diagnosisDigital pathology systemIntegration of whole slide imagesComputer workstationDiagnostic equivalenceImage equivalenceTest environmentPathology practiceWorkloadFood and DrugAmpullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes
Wong W, Lowery M, Berger M, Kemel Y, Taylor B, Zehir A, Srinivasan P, Bandlamudi C, Chou J, Capanu M, Varghese A, Yu K, Iacobuzio‐Donahue C, Shia J, Klimstra D, Jarnagin W, Stadler Z, O’Reilly E. Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes. Cancer 2019, 125: 1441-1448. PMID: 30620386, PMCID: PMC6467723, DOI: 10.1002/cncr.31951.Peer-Reviewed Original ResearchConceptsPathogenic germline alterationsAmpullary carcinomaSomatic alterationsGermline testingSomatic testingMemorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer TargetsMemorial Sloan Kettering Cancer CenterDe-identified fashionMedian overall survivalPartial radiographic responseRare gastrointestinal cancerTargetable somatic alterationsGermline genetic alterationsSubtypes of ACOpt-in strategyRadiographic responseOverall survivalMSK-IMPACTClinicopathological featuresGermline alterationsClinical outcomesPathological subtypesGenetic alterationsClinical correlatesGastrointestinal cancer
2017
Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing
Mandelker D, Zhang L, Kemel Y, Stadler Z, Joseph V, Zehir A, Pradhan N, Arnold A, Walsh M, Li Y, Balakrishnan A, Syed A, Prasad M, Nafa K, Carlo M, Cadoo K, Sheehan M, Fleischut M, Salo-Mullen E, Trottier M, Lipkin S, Lincoln A, Mukherjee S, Ravichandran V, Cambria R, Galle J, Abida W, Arcila M, Benayed R, Shah R, Yu K, Bajorin D, Coleman J, Leach S, Lowery M, Garcia-Aguilar J, Kantoff P, Sawyers C, Dickler M, Saltz L, Motzer R, O’Reilly E, Scher H, Baselga J, Klimstra D, Solit D, Hyman D, Berger M, Ladanyi M, Robson M, Offit K. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA 2017, 318: 825-835. PMID: 28873162, PMCID: PMC5611881, DOI: 10.1001/jama.2017.11137.Peer-Reviewed Original ResearchConceptsGenetic test resultsHigh-penetrance mutationsClinical guidelinesAdvanced cancerGermline testingCancer genetic testingPotential clinical implicationsCancer predisposition genesTumor-normal sequencingAssociated with increased detectionMutation detectionGermline sequencesGuideline-based testingPublished decision rulesCancer screeningFrequency of inherited mutationsGermline findingsPreventive interventionsMain OutcomesMemorial Sloan Kettering Cancer CenterCase-mixStage IV diseasePredisposition genesClinically actionable mutationsFamily historyClinical characterization of pancreatic ductal adenocarcinomas (PDAC) with mismatch repair (MMR) gene mutations.
Hu Z, Varghese A, Shia J, Zervoudakis A, Lowery M, Yu K, Chalasani S, Robson M, Stadler Z, Caron P, Kelsen D, Klimstra D, Kelly D, O'Reilly E. Clinical characterization of pancreatic ductal adenocarcinomas (PDAC) with mismatch repair (MMR) gene mutations. Journal Of Clinical Oncology 2017, 35: e15791-e15791. DOI: 10.1200/jco.2017.35.15_suppl.e15791.Peer-Reviewed Original ResearchMemorial Sloan Kettering Cancer CenterPancreatic ductal adenocarcinomaMismatch repair genesMismatch repair deficiencyMutational burdenGermline mutationsFollow-upTumor next generation sequencingNext generation sequencingSomatic mutationsPersonal/family history of cancerImmune oncology agentsResponse to immunotherapyCheckpoint inhibitor trialsLynch syndromePrognostically favorable subgroupHistory of cancerResectable diseaseUnresectable tumorsMismatch repairFavorable subgroupMSK-IMPACTInhibitor trialsPDAC patientsDuctal adenocarcinoma
2016
Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA
Schrader K, Cheng D, Joseph V, Prasad M, Walsh M, Zehir A, Ni A, Thomas T, Benayed R, Ashraf A, Lincoln A, Arcila M, Stadler Z, Solit D, Hyman D, Zhang L, Klimstra D, Ladanyi M, Offit K, Berger M, Robson M. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. JAMA Oncology 2016, 2: 1-8. PMID: 26556299, PMCID: PMC5477989, DOI: 10.1001/jamaoncol.2015.5208.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorDNA Mutational AnalysisFemaleGene Expression ProfilingGenetic Predisposition to DiseaseGerm-Line MutationHumansMaleMiddle AgedModels, GeneticNeoplasmsNew York CityPhenotypePrecision MedicinePredictive Value of TestsPrognosisRisk AssessmentRisk FactorsConceptsTumor-normal sequencingPathogenic germline variantsGermline variantsAdvanced cancer diagnosisClinical tumor sequencingCancer susceptibility genesTumor sequencingMemorial Sloan Kettering Cancer CenterStudies of targeted agentsIndividual cancer typesTumor genetic sequencingGermline findingsProportion of individualsTumor-specific variantsMendelian disease genesTargetable genetic alterationsCancer susceptibilityMatched normal DNACancer diagnosisTargeted tumor sequencingSingle-gene disordersCancer CenterMSK-IMPACTTumor profilingSomatic alterations
2015
Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone
Konstantinidis I, Groot Koerkamp B, Do R, Gönen M, Fong Y, Allen P, D'Angelica M, Kingham T, DeMatteo R, Klimstra D, Kemeny N, Jarnagin W. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer 2015, 122: 758-765. PMID: 26695839, PMCID: PMC4764409, DOI: 10.1002/cncr.29824.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBile Duct NeoplasmsBile Ducts, IntrahepaticCamptothecinCholangiocarcinomaDeoxycytidineDisease-Free SurvivalFemaleFloxuridineFluorouracilGemcitabineHepatic ArteryHumansInfusions, Intra-ArterialIrinotecanMaleMiddle AgedMitomycinRetrospective StudiesSurvival RateConceptsHepatic arterial infusionHepatic arterial infusion chemotherapySystemic chemotherapyIntrahepatic cholangiocarcinomaOverall survivalUnresectable tumorsPatients treated with systemic chemotherapyCombination groupCombination of systemic chemotherapyMemorial Sloan Kettering Cancer CenterAssociated with longer survivalAssociated with poor survivalMedian overall survivalUnresectable intrahepatic cholangiocarcinomaArterial infusion chemotherapyLymph node diseaseOutcomes of patientsLog-rank testKaplan-Meier analysisAssociated with greater survivalComplete resectionInfusion chemotherapyConsecutive patientsNode diseaseArterial infusion
2009
Pancreatic adenocarcinoma in a young patient population—12‐year experience at Memorial Sloan Kettering Cancer Center
Duffy A, Capanu M, Allen P, Kurtz R, Olson S, Ludwig E, Klimstra D, O'Reilly E. Pancreatic adenocarcinoma in a young patient population—12‐year experience at Memorial Sloan Kettering Cancer Center. Journal Of Surgical Oncology 2009, 100: 8-12. PMID: 19384918, DOI: 10.1002/jso.21292.Peer-Reviewed Original ResearchConceptsMedian overall survivalPancreatic ductal adenocarcinomaOverall survivalFamily history of PDACStage I-II diseaseRetrospective analysis of patientsStage III-IV patientsCases of pancreatic ductal adenocarcinomaMemorial Sloan Kettering Cancer CenterCohort of young patientsAJCC stage IVLocalized resectable diseaseYounger population of patientsInstitutional tumor registryKaplan-Meier methodIII-IV patientsAnalysis of patientsLog-rank testCohort of patientsPositive family historyPopulation of patientsAdjuvant gemcitabineInoperable diseaseResectable diseaseAdjuvant chemoradiation
2004
Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases
Brenner B, Shah M, Gonen M, Klimstra D, Shia J, Kelsen D. Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases. British Journal Of Cancer 2004, 90: 1720-1726. PMID: 15150595, PMCID: PMC2409752, DOI: 10.1038/sj.bjc.6601758.Peer-Reviewed Original ResearchConceptsVeterans Administration Lung Study GroupSmall-cell lung cancerSmall-cell carcinomaTumor histologyLung cancerPositive family cancer historyMemorial Sloan Kettering Cancer CenterNon-small-cell cancerPlatinum-based regimensPrimary tumor locationPredisposing medical conditionsGastrointestinal tractFamily cancer historyMetachronous tumorsPrognostic factorsTumor locationClinicopathological featuresClinical entityRetrospective studyAggressive malignancyClinical impactTNM stageStudy groupTreatment outcomesGastrointestinal sites
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply